Residual Signals: Transcriptomic Surveillance and Multi-Domain Gene-Signature Mapping for Early Breast Cancer MRD Detection

Molecular Residual Disease as a Functional Continuum

Minimal residual disease in breast cancer represents not a static remnant of post-therapy cellular survival but a dynamic biochemical continuum shaped by persistent transcriptional dysregulation. Residual tumor cells exhibit aberrant expression patterns that influence immune crosstalk, metabolic reprogramming, and microenvironmental adaptation, making their detection far more complex than the identification of isolated mutations in circulating DNA. Their gene expression output carries the imprint of dormant progenitor states, stress-response signaling, and evasion programs that cannot be reconstructed solely from somatic sequence changes. Transcriptomic approaches therefore expand the interpretive window by observing functional outputs that mirror cellular activity rather than genomic snapshots. These biological features embed MRD within a broader physiology of tissue repair, fibroblast signaling, and immune surveillance, all of which shape the molecular environment from which cfmRNA signatures emerge. Understanding this continuum clarifies why mutation-centric assays often underestimate MRD burden, especially in early-stage disease and post-surgical contexts.

Circulating cell-free mRNA amplifies the interplay between tumor cells and non-tumor microenvironment, generating a multidimensional signal dominated by transcriptionally active niches rather than residual DNA fragments alone. Tumor-associated macrophages, endothelial cells, dormant tumor-initiating cells, and stromal fibroblasts collectively contribute transcriptional material into circulation, each modulating distinct pathways connected to tumor maintenance. These signals convey the degree of residual inflammatory stress, angiogenic remodeling, and DNA repair activation that persists long after visible disease is removed. Because these pathways reflect ongoing biological processes, their detection offers a real-time measure of tumor physiology rather than a passive measurement of cell death products. Moreover, cfmRNA signatures capture the metabolic and immunologic rewiring that precede radiographic progression, introducing a predictive dimension unavailable to ctDNA alone. Such observations demonstrate why MRD detection technologies must integrate activity-based biomarkers to identify vulnerable clinical windows before relapse emerges.

Dormant residual cells often activate atypical signaling architectures that differ markedly from those of bulk primary tumors. These include suppression of proliferative transcription factors, activation of stress-responsive kinases, and mobilization of DNA repair machinery that maintains genomic stability during long quiescent intervals. Because dormant cells cycle infrequently, they release minimal ctDNA, making ctDNA-based assays intrinsically insensitive in the interval preceding relapse. Their mRNA output, however, often increases when dormancy programs shift, particularly when cells respond to endocrine withdrawal, hypoxia, or microenvironmental destabilization. This transcriptional awakening produces molecular patterns that foreshadow phenotypic escape from dormancy, allowing transcriptomic MRD tools to detect recurrence trajectories long before they manifest clinically. The dynamic nature of these signatures makes them indispensable for comprehensively mapping post-treatment biology.

The molecular continuum of MRD forms the conceptual foundation for next-generation surveillance assays that integrate tumor-derived signals with non-tumor transcriptional noise. As research evolves from mutation detection toward multi-domain functional sensing, understanding the behavior of residual disease at the transcriptomic level becomes central to improving detection sensitivity. This sets the stage for examining how multi-spectral biomarkers—spanning tumor, immune, and microenvironmental interactions—are computationally fused into coherent MRD signatures. To appreciate this integration, the following section explores how patient-derived gene signatures achieve predictive resolution that surpasses single-analyte approaches. With this transition, the focus now shifts from molecular behavior to how multi-marker biology is algorithmically encoded into MRD tools.

Multi-Spectral Biomarker Integration in Transcriptomic MRD Detection

The OncoMRD BREAST platform leverages multi-spectral biomarkers by mapping hyperactive gene expression across tumor and non-tumor compartments, creating a personalized molecular fingerprint for each patient. By combining cfmRNA from circulating tumor remnants with signals derived from stromal and immune components, the assay captures the reciprocal biochemical exchanges that fuel residual disease. These exchanges involve feedback loops among T-cell receptor components, protein-containing complexes, and co-receptor activity modules that reflect immune modulation alongside tumor adaptation. Integrating these diverse inputs produces a composite signal resistant to the silencing effects that often diminish ctDNA availability in low-shedding environments. Through this multi-domain capture, the assay identifies biological activity that extends beyond mutation presence, revealing functional states that mutation-only strategies cannot reconstruct. As a result, the gene signature becomes a living map of tumor behavior, responsive to treatment-induced perturbations.

This multi-layer integration is strengthened by high-throughput plasma transcriptomics, which quantifies hundreds of pathway-associated genes across proliferative, DNA-repair, angiogenic, and stress-response networks. Tumor-specific signatures emerge from the contrast between these signals and normal expression baselines derived from tissue references, allowing aberrant transcriptional activity to be distinguished from physiologic noise. Differential activation of pathways such as TP53 signaling, antigen presentation, and FGF-driven endocrine resistance creates a profile that mirrors the tumor’s functional architecture. Hyperactivity in these pathways serves as a surrogate for malignant potential, marking residual cell populations that evade immune surveillance or undergo metabolic adaptation. These transcriptional mosaics thus reflect the cumulative output of genomic alterations and microenvironmental pressures, making them uniquely suited for detecting MRD. This establishes transcriptomic profiling as a dynamic, rather than static, representation of residual risk.

Patient-derived signatures capture individualized tumor behavior by mapping overexpressed biomarkers to clinical features such as hypoxia, microsatellite activity, and genomic disruption. These associations translate tumor-specific expression patterns into quantitative risk indicators that strengthen prognostic interpretation. When overexpressed genes correlate with mutation burden and pathway disruption, they reveal an underlying mechanistic logic connecting gene expression outputs to oncogenic stress. This mechanistic link allows clinicians to infer biological processes—such as DNA repair activation or immune suppression—that reflect ongoing tumor viability. Importantly, patient-unique signatures reduce reliance on canonical mutation panels that may overlook clinically relevant but transcriptionally dominant pathways. Such personalization enables MRD detection even when sequencing fails to identify actionable mutations.

These integrated biomarker systems redefine MRD analysis by transforming gene expression into a computationally tractable signal capable of monitoring treatment response and relapse trajectory. The fusion of transcriptomics with tumor-derived gene signatures thus forms an adaptable framework for real-time clinical surveillance, especially where mutation-based assays fall short. The next section builds on this integration by examining how scoring algorithms translate multi-gene expression activity into interpretable risk values. Having mapped the biological origins of these signatures, we now turn to the computational structures that convert them into clinical decision tools.

Computational Scoring Architectures for Personalized MRD Quantification

At the core of the OncoMRD BREAST assay lies a scoring algorithm that transforms raw transcriptomic measurements into clinically interpretable indices of MRD burden. This computation weighs gene expression levels across multiple cancer-associated pathways, assigning relevance values based on pathway disruption, transcriptional drift, and biological plausibility. Hyperactive biomarkers—spanning DNA repair, transcription factor regulation, TP53 modulation, and immune signaling—contribute to a composite score reflecting ongoing tumor activity. The algorithm harmonizes expression inputs by normalizing counts against reference standards to reduce technical variability introduced during RNA extraction and sequencing. This process creates a unified metric that incorporates both tumor-derived and microenvironment-derived signals to indicate whether residual activity persists. As a result, the final score captures both direct and ancillary markers of tumor behavior.

By quantifying transcript abundance relative to tissue-linked baselines, the scoring system distinguishes pathological activity from physiological transcriptional fluctuations. This distinction is crucial because circulating mRNA is produced by multiple cell types, and not all signals correspond to malignant processes. Gene co-expression matrices enhance the algorithm by mapping relationships among biomarkers and clinically relevant genes, revealing coordinated transcriptional programs associated with residual disease. For example, co-expression with BRCA1, BRCA2, ATM, ESR1, and PIK3CA anchors the MRD score within pathways deeply intertwined with breast tumor biology. These correlations act as computational safeguards that prevent false positives resulting from nonspecific inflammatory or stress-related transcription. By embedding transcriptomic context into scoring logic, the algorithm preserves biological fidelity while maximizing detection sensitivity.

The scoring architecture acknowledges tumor heterogeneity by accounting for expression convergence across pathways that undergo similar dysregulation despite distinct genetic alterations. Molecular convergence allows the algorithm to interpret pathway-level shifts even when the underlying mutations differ among patients. This characteristic makes transcriptomic scoring robust against the evolutionary plasticity of breast cancer, where clonal divergence may produce disparate mutational landscapes without altering functional gene expression trajectories. The algorithm therefore detects MRD by measuring pathway activation rather than relying exclusively on mutation recurrence. Such resilience is particularly valuable in endocrine-resistant or therapy-adapted tumors that maintain aggressive phenotypes while reducing ctDNA shedding. Through this lens, scoring transcends genomic obstacles and instead relies on transcriptional fidelity.

As computational scoring converts multi-gene signatures into actionable risk values, it provides a bridge between molecular biology and clinical practice. These scores allow clinicians to monitor therapy response, track dormancy escape, and anticipate relapse without waiting for radiographic confirmation. This transition from molecular quantification to clinical interpretation sets the foundation for integrating MRD assessment into therapeutic monitoring. To explore how these computational insights translate into patient outcomes, the next section examines how transcriptomic MRD tracking performs alongside standard imaging modalities and other liquid biopsy technologies. With scoring established, practical deployment becomes the natural focus.

Clinical Performance and Integration of Transcriptomic MRD Surveillance

Transcriptomic MRD detection offers an unprecedented ability to monitor treatment response by capturing the biochemical activity of residual tumors in real time. Because cfmRNA originates from both tumor and microenvironmental sources, it reflects dynamic physiological processes rather than the passive release of degraded genetic fragments. This dynamic nature allows transcriptomic assays to detect subtle deviations in tumor activity that often precede imaging abnormalities. As patients progress through adjuvant therapy, changes in gene-expression-driven MRD scores signal therapeutic impact or resistance trajectories with immediate clinical relevance. Even in early-stage disease, where ctDNA shedding is extremely low, transcriptomic tools maintain sensitivity by leveraging multi-pathway activity rather than relying solely on tumor DNA burden. Thus, transcriptomic MRD tracking becomes a companion modality to clinical imaging rather than a competing technology.

When compared with positron emission tomography and computed tomography, transcriptomic MRD surveillance captures upstream molecular transitions that imaging can only detect once sufficient metabolic or structural change has occurred. Transcriptomic assays identify changes in pathway hyperactivity that portend transformation from dormant to proliferative states, offering a predictive edge unavailable to radiologic tools. These molecular shifts correlate with clinical response categories such as complete remission, partial response, or stable disease, enabling clinicians to gauge treatment depth before radiographic evidence consolidates. This is especially useful in metastatic settings, where maintaining suppression of biologically active clones is crucial for prolonging survival. As transcriptomic scores evolve across clinical intervals, they provide a continuous measure that complements episodic imaging assessments. This synergy redefines therapeutic monitoring as multidimensional rather than episodic.

The clinical value of this approach becomes particularly apparent in cases where mutation-based assays, CTC enumeration, and protein biomarkers fail to detect disease signals. Transcriptomic MRD scores succeed in scenarios where ctDNA-based methods are limited by low shedding, genomic noise from non-tumor cells, or mutations that lack sensitivity for residual disease detection. This broader surveillance capacity is rooted in the assay’s ability to integrate multiple biological domains, thereby detecting residual activity even when genetic markers appear silent. As treatment landscapes evolve toward personalized dosing strategies, transcriptomic MRD monitoring provides the granularity needed to tailor therapy intensity to molecular response depth. These capabilities highlight the role of expression-based diagnostics in refining precision oncology.

As transcriptomic MRD surveillance continues to integrate into clinical pathways, it will require expanded validation through prospective studies focused on intervention-driven outcomes. This next phase of evolution emphasizes linking score-guided therapy adjustments to relapse prevention and survival benefit, enabling MRD tools to transition from observational markers into interventional triggers. The growing convergence of molecular signaling, computational analytics, and clinical interpretation marks a transformative moment in breast cancer management. With the scientific foundation established, this final transition underscores the broader importance of transcriptomic MRD as a future-defining modality across solid tumors. The article now concludes with topic blurbs summarizing the scientific theme rather than the narrative.

Study DOI: https://doi.org/10.3390/onco5030035

Engr. Dex Marco Tiu Guibelondo, B.Sc. Pharm, R.Ph., B.Sc. CompE

Editor-in-Chief, PharmaFEATURES